Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV 550 (Virgan, ganciclovir) in acute adenoviral keratoconjunctivitis
2007-002455-16Phase 2Completed
- Sponsor
- Laboratoires Théa
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in adenoviral keratoconjunctivitis (EKC) comparing GV 550 (Virgan, ganciclovir) with Placebo (2 arms). Primary endpoint: Change in ocular inflammation signs from Day 0 to Day 4. Started Jul 2007; status: completed.
02
Drugs
GV550
03
Conditions
adenoviral keratoconjunctivitis (EKC)
Beyond the preview
Go deeper on 2007-002455-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002455-16.